dexnefopam

Dexnefopam is the single-enantiomer form of nefopam that was developed by Sosei, now Nxera Pharma, under the code AD-337 as a small-molecule analgesic and neuromodulatory candidate. Public clinical-trial records verify AD-337 in a completed exploratory study in fibromyalgia in women. Based on public drug-database and literature context, dexnefopam appears to have been pursued as the pharmacologically preferred enantiomer of nefopam, with monoamine reuptake inhibition involving serotonin and norepinephrine transporters as the best-supported intended mechanism, although the exact target profile for the isolated enantiomer is not well characterized in authoritative primary public sources. Development appears to have remained early and there is no evidence of approval.

Other names

dexnefopam